| MyoKardia is a clinical-stage biopharmaceutical company. Co.'s initial research has focused on genetic mutations in sarcomeric proteins of the heart muscle. Co.'s primary therapeutic candidate, mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). In addition to mavacamten, Co.'s programs include Danicamtiv, an orally-administered small molecule designed to increase cardiac contractility without impairing diastolic filling in patients with systolic heart failure; and MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation. We show 23 historical shares outstanding datapoints in our coverage of MYOK's shares outstanding history.|
Understanding the changing numbers of MYOK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MYOK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MYOK by allowing them to research MYOK shares outstanding history
as well as any other stock in our coverage universe.